scorecardresearch
Add as a preferred source on Google
Saturday, January 3, 2026
TopicNovartis

Topic: Novartis

India approves Zolgensma, one of world’s costliest drugs. Why it’s sparked hope, but also concern

Zolgensma is the only drug that promises a cure for Spinal Muscular Atrophy, provided it is administered to affected children before the symptoms appear.

In Delhi hospitals, thalassemia patients suffer as life-saving Desferal scarce, set to become 50% costlier

Doctors & patients confirm acute shortage of the drug in hospitals, even as manufacturer Novartis maintains there is no shortage in supply.

2 jabs a year to keep bad cholesterol at bay — breakthrough treatment to launch in India this month

Novartis India, the company that has the import and marketing permission for Inclisiran, refused to divulge the price of the drug in India, but market sources say it is going to be Rs 1.2 lakh per jab.

Novartis, Eli Lilly oppose compulsory licences for breast cancer drugs, say sales up despite price

Pharma giants were responding to petition in Kerala HC seeking compulsory licences for their HER2-negative breast cancer drugs, which would allow cheaper, generic versions to be made.

On Camera

India’s most consequential decade & chronicling it as part of the dream team of journalism

You’d think the decade of 1985-95 is long over. Not really. The issues that erupted in that decade are still shaping Indian conversations.

India’s urban co-op banks are turning the page—crisis to cautious revival, one metric at a time

With bad loans shrinking & capital buffers stronger, urban co-op banks’ new umbrella body NUCFDC is now prioritising rollout of digital transformation.

Greece looking at TATA’s WhAP infantry combat vehicle for army procurement

If deal goes through, Greece will be 2nd foreign country to procure vehicle. Morocco was first; TATA Group has set up manufacturing unit there with minimum 30 percent indigenous content.

A year-end Mea Culpa in National Interest—The Army-Islam combo doesn’t kill democracy

Many of you might think I got something so wrong in National Interest pieces written this year. I might disagree! But some deserve a Mea Culpa. I’d deal with the most recent this week.